Cargando…

Statement for Appropriate Clinical Use of PCSK9 Inhibitors

Detalles Bibliográficos
Autores principales:	Nohara, Atsushi, Ohmura, Hirotoshi, Okazaki, Hiroaki, Ogura, Masatsune, Kitagawa, Kazuo, Koseki, Masahiro, Sato, Kayoko, Tsukamoto, Kazuhisa, Yamashita, Shizuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2018
Materias:	Statement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099074/ https://www.ncbi.nlm.nih.gov/pubmed/29899173 http://dx.doi.org/10.5551/jat.45229

Ejemplares similares

Current Diagnosis and Management of Tangier Disease
por: Koseki, Masahiro, et al.
Publicado: (2021)

Statement on the safety of d‐ribose
por: Turck, Dominique, et al.
Publicado: (2018)

Statement on the active substance flupyradifurone
por: Hernandez Jerez, Antonio, et al.
Publicado: (2022)

Statement on the active substance acetamiprid
por: Hernandez Jerez, Antonio, et al.
Publicado: (2022)

Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee
por: Abola, Maria Teresa B, et al.
Publicado: (2020)

ESR Statement on the Validation of Imaging Biomarkers
Publicado: (2020)

ESR statement on portable ultrasound devices
Publicado: (2019)

Statement on non‐dietary exposure on diquat
Publicado: (2018)

Statement on risk mitigation measures on cypermethrin
Publicado: (2019)

ESR statement on the stepwise development of imaging biomarkers
Publicado: (2013)

ESR statement on good scientific practice and publishing
Publicado: (2012)

Position Statement on Indications of Echocardiography in Adults - 2019
por: Barberato, Silvio Henrique, et al.
Publicado: (2019)

Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019
por: Serrano Jr., Carlos V., et al.
Publicado: (2019)

ESR statement on new approaches to undergraduate teaching in Radiology
Publicado: (2019)

Statement concerning the review of the approval of the active substance ipconazole
Publicado: (2022)

Scientific statement on the maximum residue levels for potassium phosphonates
Publicado: (2022)

Statement concerning the review of the approval of the active substance pirimicarb
Publicado: (2023)

Statement on the BfR opinion regarding the toxicity of 2‐chloroethanol
por: Borroto, Jorge, et al.
Publicado: (2022)

European Commission guidelines on clinical audit. Statement by the European Society of Radiology
Publicado: (2011)

Statement on safety of cannabidiol as a novel food: data gaps and uncertainties
por: Turck, Dominique, et al.
Publicado: (2022)

Statement on how to interpret the QPS qualification on ‘acquired antimicrobial resistance genes’
por: Koutsoumanis, Konstantinos, et al.
Publicado: (2023)

ESR statement on radiation protection: globalisation, personalised medicine and safety (the GPS approach)
Publicado: (2013)

Scientific statement on the coverage of bats by the current pesticide risk assessment for birds and mammals
por: Hernández‐Jerez, Antonio, et al.
Publicado: (2019)

Attracting the next generation of radiologists: a statement by the European Society of Radiology (ESR)
Publicado: (2022)

Statement on the revised targeted risk assessment for certain maximum residue levels for nicotine
Publicado: (2023)

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity
por: Ross, Robert, et al.
Publicado: (2020)

Vascular Ultrasound Statement from the Department of Cardiovascular Imaging of the Brazilian Society of Cardiology - 2019
por: dos Santos, Simone Nascimento, et al.
Publicado: (2019)

Ethics of artificial intelligence in radiology: summary of the joint European and North American multisociety statement
por: Geis, J. Raymond, et al.
Publicado: (2019)

Statement on the derivation of Health‐Based Guidance Values (HBGVs) for regulated products that are also nutrients
por: More, Simon, et al.
Publicado: (2021)

Statement on the dietary risk assessment for the proposed temporary maximum residue level for chlormequat in oyster mushrooms
Publicado: (2019)

Statement on additional scientific evidence in relation to the essential composition of total diet replacement for weight control
por: Castenmiller, Jacqueline, et al.
Publicado: (2021)

Statement on in vitro protein digestibility tests in allergenicity and protein safety assessment of genetically modified plants
por: Naegeli, Hanspeter, et al.
Publicado: (2021)

Statement of the Italian Association of Medical Physics (AIFM) task group on radiation dose monitoring systems
por: Ria, Francesco, et al.
Publicado: (2022)

EFSA statement on the requirements for whole genome sequence analysis of microorganisms intentionally used in the food chain
Publicado: (2021)

Statement on the relevance of the groundwater metabolite RH‐2651 in the assessment of confirmatory data on the active substance tebufenozide
Publicado: (2021)

Position Statements
Publicado: (2009)

Statement of Retraction
Publicado: (2012)

Position Statements
Publicado: (2011)

Position Statements
Publicado: (2010)

Statement of clarification
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_adg275h78abeke8tgocle9561t